Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones

Journal of Neurochemistry

Volumn 92, Issue 6, 2005, Pages 1386-1398

  Bösel, Julian ^a   Gandor, Florin ^a   Harms, Christoph ^a   Synowitz, Michael ^b   Harms, Ulrike ^a   Djoufack, Pierre Chryso ^c   Megow, Dirk ^a   Dirnagl, Ulrich ^a   Hörtnagl, Heide ^a   Fink, Klaus B ^c   Endres, Matthias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Excitotoxicity; Neuroprotection; Statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; APOPTOSIS INDUCING FACTOR; ATORVASTATIN; CALCIUM; CHOLESTEROL; GLUTAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPRENOID; LACTATE DEHYDROGENASE; MEVALONIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROPIDIUM IODIDE; TETRAZOLIUM;

ANIMAL CELL; APOPTOSIS; ARTICLE; BRAIN CELL; BRAIN CORTEX; CALCIUM CELL LEVEL; CELL DAMAGE; CELL NUCLEUS; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME RELEASE; EXCITOTOXICITY; IN VITRO STUDY; MITOCHONDRIAL RESPIRATION; NEUROPROTECTION; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RAT; STAINING;

ACYL COENZYME A; ANIMALS; APOPTOSIS; CALCIUM SIGNALING; CELLS, CULTURED; CEREBRAL CORTEX; GLUCOSE; GLUTAMIC ACID; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIA; HYPOXIA-ISCHEMIA, BRAIN; MITOCHONDRIA; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PYRROLES; RATS; RECEPTORS, GLUTAMATE;

EID: 20144385721     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02980.x     Document Type: Article

References (59)

1. Amarenco P. (2001) Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology 57, S35-S44.
2. 2+ concentrations. J. Exp. Biol. 201, 1141-1152.
3. Bösel J. and Endres M. (2002) Clinical use of statins. Akt. Neurol. 29, 254-261.
4. Brewer G. J. (1995) Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum and dentate gyms. J. Neurosci. Res. 42, 674-683.
5. Brewer G. J., Torricelli J. R., Evege E. K. and Price P. J. (1993) Optimized survival of hippocampal neurons in B-27supplemented neurobasal™, a new serum-tree medium combination. J. Neurosi. Res. 35, 567-576.
6. Bruer U., Weih M. K., Isaev N. K., Meisel A., Ruscher K., Bergk A., Trendelenburg G., Wiegand F., Victorov I. V. and Dirnagl U. (1997) Induction of tolerance in rat cortical neurons: hypoxic preconditioning. FEBS Lett. 414, 117-121.
7. Choi D. W. (1995) Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends. Neurosci. 18, 58-60.
8. Cottrell J. R., Dube G. R., Egles C. and Liu G. (2000) Distribution, density, and clustering of functional glutamate receptors before and after synaptogenesis in hippocampal neurons. J. Neurophysiol. 84, 1573-1587.
9. Cucchiara B. and Kasner S. E. (2001) Use of statins in CNS disorders. J. Neurol. Sci. 187, 81-89.
10. Denizot F. and Lang R. (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the terrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Meth. 22, 271-277.
11. Endres M. and Laufs U. (2004) Effects of statins on endothelium and signalling mechanisms. Stroke 35 (11:suppl. 1), 2708-2711.
12. Endres M., Laufs U., Huang Z., Nakamura T., Huang P. L., Moskowitz M. A. and Liao J. K. (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 95, 8880-8885.
13. Fan Q. W. YuW., Gong J. S., Zou K., Sawamura N., Senda T., Yanagisawa K. and Michikawa M. (2002) Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J. Neurochem. 80, 178-190.
14. Farinelli S. E. and Greene L. A. (1996) Cell cycle blockers mimosine, ciclopirox and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J. Neurosci. 16, 1150-1162.
15. Fassbender K., Stroick M., Bertsch T. et al. (2002) Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59, 1257-1258.
16. Fisher A., Mantione C. R., Abraham D. J. and Hanin I. (1982) Long-term central cholinergic hypofunction in mice by ethylcholine aziridinium ion (AF64A) in vivo. J. Pharmacol. Exp. Ther. 222, 140-145.
17. Freeman T. C., Dixon A. K., Campbell E. A., Tait T. M., Richardson P. J., Rice K. M., Maslen G. L., Metcalfe A. D., Streuli C. H. and Bentley D. R. (1998) Expression mapping of mouse genes. MGI Direct Data Submission, MGI Accession ID: 1199209.
18. Furukawa K. and Mattson M. P. (1998) The transcription factor NF-kappaB mediates increases in calcium currents and decreases in NMDA- and AMPA/kainate-induced currents induced by Tumor Necrosis Factor-alpha in hippocampal neurons. J. Neurochem. 70, 1876-1886.
19. Garcia-Roman N., Alvarez A. M., Toro M. J., Montes A. and Lorenzo M. J. (2001) Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol. Cell. Neurosci. 17, 329-341.
20. Greisenegger S., Müllner M., Tentschert S., Lang W. and Lalouschek W. (2004) Effects of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J. Neurol. Sci. 221, 5-10.
21. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450.
22. Gwag B. J., Lobner D., Koh J. Y. and Choi D. W. (1995) Blockade of glutamate receptors unmasks neuronal apoptosis after oxygen-glucose deprivation in vitro. Neuroscience 68, 615-619.
23. Hamelin B. A. and Turgeon J. (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends. Pharmacol. Sci. 19, 26-37.
24. Harms C., Lautenschlager M., Bergk A., Katchanov J., Kapinya K., Herwig U., Megow D., Dirnagl U., Weber J. R. and Hörtnagl H. (2001) Differential mechanisms of neuroprotection by 17-beta-estradiol in apoptotic versus necrotic neurodegeneration. J. Neurosci. 21, 2600-2609.
25. Harms C., Bösel J., Lautenschlager M., Harms U., Braun J. S., Hörtnagl H., Dirnagl U., Kwiatkowski D. J., Fink K. and Endres M. (2004) Neuronal gelsolin prevents apoptosis by enhancing actin depolymerization. Mol. Cell. Neurosci. 25, 69-82.
26. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7-22.
27. Hebert P. R., Gaziano J. M. and Hennekens C. H. (1995) An overview of trials of cholesterol lowering and risk of stroke. Arch. Intern. Med. 155, 50-55.
28. Hess D. C., Demchuk A. M., Brass L. M. and Yatsu F. M. (2000) HMG-CoA reductase inhibitors (statins). A promising approach to stroke prevention. Neurology 54, 790-796.
29. Jick H., Zornberg G. L., Jick S. S., Seshadri S. and Drachmann D. A. (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
30. Koh J. Y. and Choi D. W. (1987) Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J. Neurosci. Meth. 20, 83-90.
31. Kwak B., Mulhaupt F., Myit S. and Mach F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399-1402.
32. Lautenschlager M., Onufriev M. V., Gulyaeva N. V. et al. (2000) Role of nitric oxide in the ethylcholine aziridinium model of delayed apoptotic neurodegeneration in vivo and in vitro. Neuroscience 97, 383-393.
33. Liao J. K. (2002) Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol. 86, 5-18.
34. Mao X., Moerman A. M. and Barger S. W. (2002) Neuronal kappaB-binding factors consist of Sp1-related proteins. J. Biol. Chem. 277, 44 911-44 919.
35. Marti-Fabregas J., Gomis M., Arboix A. et al. (2004) Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 35, 1117-1123.
36. Meske V., Albert F., Richter D., Schwarze J. and Ohm T. G. (2003) Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur. J. Neurosci. 17, 93-102.
37. Michikawa M. and Yanagisawa K. (1999) Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J. Neurochem. 72, 2278-2285.
38. Minta A., Kao J. P. and Tsien R. Y. (1989) Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. J. Biol. Chem. 264, 8171-8178.
39. Parpura V., Basarsky T. A., Liu F., Jeftinija K., Jeftinija S. and Haydon P. G. (1994) Glutamate-mediated astrocyte-neuron signalling. Nature 369, 744-748.
40. Rader D. J. (2003) Therapy to reduce the risk of coronary heart disease. Clin. Cardiol. 26, 2-8.
41. Rombouts K., Kisanga E., Hellemans K., Wielant A., Schuppan D. and Geerts A. (2003) Effects of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J. Hepatol. 38, 546-572.
42. Sans N., Petralia R. S., Wang Y. X., Blahos J. 2nd, Hell J. W. and Wenthold R. J. (2000) A developmental change in NMDA receptor-associated proteins at hippocampal synapses. J. Neurosci. 20, 1260-1271.
43. Schulz J. G., Bösel J., Stoeckel M., Megow D., Dirnagl U. and Endres M. (2004) HMG-CoA reductase inhibition causes neunte loss by interfering with geranylgeranylpyrophosphate synthesis. J. Neurochem. 89, 24-32.
44. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G. and Simons K. (1998) Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 6460-6464.
45. Simons M., Schwarzler F., Lutjohann D., von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T. and Schulz J. B. (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomised, placebo-controplled, double-blind trial. Ann. Neurol. 52, 346-350.
46. Sonnewald U., Qu H. and Aschner M. (2002) Pharmacology and toxicology of astrocyte-neuron glutamate transport and cycling. J. Pharmacol. Exp. Ther. 301, 1-6.
47. Stefanis L., Park D. S., Friedman W. J. and Greene L. A. (1999) Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons. J. Neurosci. 19, 6235-6247.
48. Stein A. (2002) Management of dyslipidemia. Am. Heart. J. 144, 543-550.
49. Tanaka T., Tatsuno I., Uchida D. et al. (2000) Geranylgeranyl- pyrophosphate, an isoprenoid of mevalonate cascade, is a critcal compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA inhibition. J. Neurosci. 20, 2852-2859.
50. Thornton C., Yaka R., Dinh S. and Ron D. (2003) H-Ras modulates N-Methyl-D-aspartate function via inhibition of Src tyrosine kinase activity. J. Biol. Chem. 278, 23823-23829.
51. Tingley W. G., Ehlers M. D., Kameyama K., Doherty C., Ptak J. B., Riley C. T. and Huganir R. L. (1997) Characterization of the protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J. Biol. Chem. 272, 5157-5166.
52. Tsiara S., Elisaf M. and Mikhailidis D. P. (2003) Early vascular benefits of statin therapy. Curr. Med. Res. Opin. 19, 540-556.
53. Vernadakis A. (1996) Glia-neuron intercommunications and synaptic plasticity. Prog. Neurobiol. 49, 185-214.
54. Wagner A. H., Gebauer M., Güldenzoph B. and Hecker M. (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Thromb. Vasc. Biol. 22, 1784-1789.
55. Weitz-Schmidt G. (2002) Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23, 482-486.
56. White H. D., Simes R. J., Anderson N. E. et al. for the LIPID Study Group (2000) Pravastatin therapy and the risk of stroke. N. Eng. J. Med. 343, 317-326.
57. Wolozin B., Kellman W., Rousseau P., Celesia G. G. and Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443.
58. Zacco A., Togo J., Spence K., Ellis A., Lloyd D., Furlong S. and Piser T. (2003) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J. Neurosci. 23, 11 104-11 111.
59. Zhang J., Shi F., Badour K., Deng Y., McGavin M. K. H. and Siminovitch K. A. (2002) WASp verprolin homology, cofilin homology, and acidic region domain-mediated actin polymerisation is required for T cell development. Proc. Natl Acad. Sci. 99, 2240-2245.